{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:48:05Z","timestamp":1788871685437,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"EntreMed, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.ejca.2012.07.020","type":"journal-article","created":{"date-parts":[[2012,8,21]],"date-time":"2012-08-21T11:35:39Z","timestamp":1345548939000},"page":"121-131","source":"Crossref","is-referenced-by-count":43,"title":["ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer"],"prefix":"10.1016","volume":"49","author":[{"given":"Ursula A.","family":"Matulonis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lasonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Tew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afra","family":"Yehwalashet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Matei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kian","family":"Behbakht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Grothusen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gini","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nita K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Arnott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Bray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Brokx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Castonguay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Mackay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn F.","family":"Sidor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit M.","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2012.07.020_b0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer Statistics 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin Jan\u2013Feb"},{"key":"10.1016\/j.ejca.2012.07.020_b0010","first-page":"25","article-title":"Targeted treatment of recurrent-platinum resistant ovarian cancer; current and emerging therapies","volume":"3","author":"Mantia-Smaldone","year":"2011","journal-title":"Cancer Manage Res"},{"issue":"1","key":"10.1016\/j.ejca.2012.07.020_b0015","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1158\/1535-7163.MCT-10-0574","article-title":"ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action","volume":"10","author":"Fletcher","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2012.07.020_b0020","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1158\/1078-0432.CCR-10-2144","article-title":"Phase 1 safety, pharmacokinetic and pharmacodynamics study of ENMD-2076, a novel angiogenic and aurora kinase inhibitor in patients with advanced solid tumors","volume":"174","author":"Diamond","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2012.07.020_b0025","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma; a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.07.020_b0030","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.07.020_b0165","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for themedian survival time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"key":"10.1016\/j.ejca.2012.07.020_b0040","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev.pathol.4.110807.092246","article-title":"Ovarian cancer","volume":"4","author":"Cho","year":"2007","journal-title":"Ann Rev Pathol Mech Dis"},{"key":"10.1016\/j.ejca.2012.07.020_b0045","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1200\/JCO.2009.23.2777","article-title":"Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer","volume":"27","author":"Matulonis","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.07.020_b0160","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1200\/JCO.2006.09.6925","article-title":"Molecularly targeted oncology therapeutics and prolongation of the QT interval","volume":"25","author":"Strevel","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.07.020_b0055","doi-asserted-by":"crossref","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"32","author":"Schmidinger","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.07.020_b0060","first-page":"128","article-title":"Reversible cardiotoxicity with tyrosine kinase inhibitors","volume":"8","author":"Frances","year":"2010","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.ejca.2012.07.020_b0065","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1634\/theoncologist.2009-0252","article-title":"Anti-vascular endothelial growth factor therapies and cardiovascular toxicity; what are the important clinical markers to target?","volume":"15","author":"Vaklavas","year":"2010","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.ejca.2012.07.020_b0070","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11912-012-0242-z","article-title":"VEGF inhibition, hypertension, and renal toxicity","volume":"14","author":"Hayman","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ejca.2012.07.020_b0075","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib; a systematic review and met-analysis of clinical trials","volume":"28","author":"Choueiri","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.07.020_b0080","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrclinonc.2009.130","article-title":"An overview of small-molecule inhibitors of VEGFR signaling","volume":"6","author":"Ivy","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2012.07.020_b0085","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2265.2008.03253.x","article-title":"Thyrotoxicosis during sunitinib treatment for renal cell carcinoma","volume":"69","author":"Grossman","year":"2008","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ejca.2012.07.020_b0090","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1634\/theoncologist.2010-0078","article-title":"Fatigue in renal cell carcinoma; the hidden burden of current targeted therapies","volume":"15","author":"Larkin","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2012.07.020_b0095","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/annonc\/mdn637","article-title":"Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab","volume":"20","author":"Scartozzi","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2012.07.020_b0100","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc2152","article-title":"Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition","volume":"7","author":"Verheul","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2012.07.020_b0105","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.07.020_b0110","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ejca.2012.07.020_b0115","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2012.07.020_b0120","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.07.020_b0125","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2010.05.033","article-title":"A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer","volume":"119","author":"Friedlander","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2012.07.020_b0130","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80mg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study","volume":"101","author":"Markman","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2012.07.020_b0135","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ygyno.2010.08.016","article-title":"Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer","volume":"114","author":"Han","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2012.07.020_b0140","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1158\/1535-7163.MCT-10-0169","article-title":"Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary","volume":"9","author":"Mabuchi","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2012.07.020_b0145","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ygyno.2011.05.009","article-title":"Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis","volume":"122","author":"Lee","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2012.07.020_b0150","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1158\/1078-0432.CCR-10-3314","article-title":"IL6-Stat3-HIF signaling and therapeutic response to the angiogenesis inhibitor, sunitinib, in ovarian clear cell cancer","volume":"17","author":"Anglesio","year":"2011","journal-title":"Clin Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491200603X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491200603X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T04:54:25Z","timestamp":1542776065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491200603X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S095980491200603X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2012.07.020","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}